Literature DB >> 23577774

Discovery of the natural anti-Gal antibody and its past and future relevance to medicine.

Uri Galili1.   

Abstract

This is a personal account of the discovery of the natural anti-Gal antibody, the most abundant natural antibody in humans, the reciprocal distribution of this antibody and its ligand the α-gal epitope in mammals and the immunological barrier this antibody has formed in porcine to human xenotransplantation. This barrier has been overcome in the recent decade with the generation of α1,3-galactosyltransferase gene-knockout pigs. However, anti-Gal continues to be relevant in medicine as it can be harnessed for various therapeutic effects. Anti-Gal converts tumor lesions injected with α-gal glycolipids into vaccines that elicit a protective anti-tumor immune response by in situ targeting of tumor cells for uptake by antigen-presenting cells. This antibody further accelerates wound and burn healing by interaction with α-gal nanoparticles applied to injured areas and induction of rapid recruitment and activation of macrophages. Anti-Gal/α-gal nanoparticle immune complexes may further induce rapid recruitment and activation of macrophages in ischemic myocardium and injured nerves, thereby inducing tissue regeneration and prevention of fibrosis.
© 2013 John Wiley & Sons A/S.

Entities:  

Keywords:  anti-Gal antibody; evolution; injury healing; primates; tumor immunotherapy; xenotransplantation; α-gal epitope; α1,3-galactosyltransferase

Mesh:

Substances:

Year:  2013        PMID: 23577774     DOI: 10.1111/xen.12034

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  15 in total

1.  Evaluation of human and non-human primate antibody binding to pig cells lacking GGTA1/CMAH/β4GalNT2 genes.

Authors:  Jose L Estrada; Greg Martens; Ping Li; Andrew Adams; Kenneth A Newell; Mandy L Ford; James R Butler; Richard Sidner; Matt Tector; Joseph Tector
Journal:  Xenotransplantation       Date:  2015-03-01       Impact factor: 3.907

2.  Biomimetic Glyconanoparticle Vaccine for Cancer Immunotherapy.

Authors:  Eliran Moshe Reuven; Shani Leviatan Ben-Arye; Hai Yu; Roberto Duchi; Andrea Perota; Sophie Conchon; Shirley Bachar Abramovitch; Jean-Paul Soulillou; Cesare Galli; Xi Chen; Vered Padler-Karavani
Journal:  ACS Nano       Date:  2019-03-11       Impact factor: 15.881

Review 3.  New insights on innate B-cell immunity in transplantation.

Authors:  Emmanuel Zorn
Journal:  Xenotransplantation       Date:  2018-05       Impact factor: 3.907

4.  Characterization and statistical modeling of glycosylation changes in sickle cell disease.

Authors:  Heather E Ashwood; Christopher Ashwood; Anna P Schmidt; Rebekah L Gundry; Karin M Hoffmeister; Waseem Q Anani
Journal:  Blood Adv       Date:  2021-03-09

Review 5.  Cancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reaction.

Authors:  Masahiro Tanemura; Eiji Miyoshi; Hiroaki Nagano; Hidetoshi Eguchi; Katsuyoshi Matsunami; Kiyomi Taniyama; Nobutaka Hatanaka; Hiroki Akamatsu; Masaki Mori; Yuichiro Doki
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

6.  Comparative Decellularization and Recellularization of Wild-Type and Alpha 1,3 Galactosyltransferase Knockout Pig Lungs: A Model for Ex Vivo Xenogeneic Lung Bioengineering and Transplantation.

Authors:  Joseph Platz; Nicholas R Bonenfant; Franziska E Uhl; Amy L Coffey; Tristan McKnight; Charles Parsons; Dino Sokocevic; Zachary D Borg; Ying-Wai Lam; Bin Deng; Julia G Fields; Michael DeSarno; Roberto Loi; Andrew M Hoffman; John Bianchi; Brian Dacken; Thomas Petersen; Darcy E Wagner; Daniel J Weiss
Journal:  Tissue Eng Part C Methods       Date:  2016-07-14       Impact factor: 3.056

7.  LEA29Y expression in transgenic neonatal porcine islet-like cluster promotes long-lasting xenograft survival in humanized mice without immunosuppressive therapy.

Authors:  L Wolf-van Buerck; M Schuster; F S Oduncu; A Baehr; T Mayr; S Guethoff; J Abicht; B Reichart; N Klymiuk; E Wolf; J Seissler
Journal:  Sci Rep       Date:  2017-06-15       Impact factor: 4.379

8.  Presentation Mode of Glycans Affect Recognition of Human Serum anti-Neu5Gc IgG Antibodies.

Authors:  Salam Bashir; Shani Leviatan Ben Arye; Eliran Moshe Reuven; Hai Yu; Cristina Costa; Manuel Galiñanes; Tomaso Bottio; Xi Chen; Vered Padler-Karavani
Journal:  Bioconjug Chem       Date:  2018-12-13       Impact factor: 4.774

Review 9.  Posttranslational Modifications and the Immunogenicity of Biotherapeutics.

Authors:  Roy Jefferis
Journal:  J Immunol Res       Date:  2016-04-14       Impact factor: 4.818

Review 10.  Characteristics of α-Gal epitope, anti-Gal antibody, α1,3 galactosyltransferase and its clinical exploitation (Review).

Authors:  Guoli Huai; Ping Qi; Hongji Yang; Yi Wang
Journal:  Int J Mol Med       Date:  2015-10-30       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.